^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    pomalidomide

    i
    Other names: CC 4047, CDC 394, CC-4047 , CDC-394, CC4047, CDC394
    Company:
    Generic mfg.
    Drug class:
    TNFα inhibitor, IL-6 inhibitor, NK cell stimulant, IL-10 stimulant, IL-1β inhibitor
    Related drugs:
    1m
    Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes (clinicaltrials.gov)
    P2, N=49, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Apr 2026 --> Apr 2027
    Trial completion date
    |
    RUNX1 (RUNX Family Transcription Factor 1) • SF3B1 (Splicing Factor 3b Subunit 1) • ASXL1 (ASXL Transcriptional Regulator 1) • SRSF2 (Serine and arginine rich splicing factor 2) • BCOR (BCL6 Corepressor) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • STAG2 (Stromal Antigen 2) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2)
    |
    Chr del(11q)
    |
    Vyxeos (cytarabine/daunorubicin liposomal formulation) • pomalidomide
    2ms
    CARTITUDE-4: A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (clinicaltrials.gov)
    P3, N=419, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Apr 2029 --> Mar 2027
    Trial completion date • IO biomarker
    |
    lenalidomide • bortezomib • cyclophosphamide • dexamethasone • pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Carvykti (ciltacabtagene autoleucel)
    2ms
    KarMMa-3: Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (clinicaltrials.gov)
    P3, N=386, Completed, Celgene | Active, not recruiting --> Completed | Trial completion date: Apr 2027 --> Apr 2026 | Trial primary completion date: Apr 2027 --> Apr 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    lenalidomide • bortezomib • Ninlaro (ixazomib) • Darzalex (daratumumab) • carfilzomib • dexamethasone • pomalidomide • Empliciti (elotuzumab) • Abecma (idecabtagene vicleucel)
    2ms
    Pomalidomide significantly enhances the antitumor immune efficacy of dendritic cell-derived exosomes from multiple myeloma patients. (PubMed, J Transl Med)
    This study provides a new strategy for enhancing the activity of DEXs derived from patients with MM, with the potential to develop DEXs as an antitumor vaccine for MM.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD80 (CD80 Molecule) • CD81 (CD81 Molecule) • CD86 (CD86 Molecule)
    |
    pomalidomide
    2ms
    Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis (clinicaltrials.gov)
    P1/2, N=53, Recruiting, Columbia University | Trial completion date: Sep 2026 --> Sep 2027 | Trial primary completion date: Sep 2026 --> Sep 2027
    Trial completion date • Trial primary completion date
    |
    Chr t(11;14)
    |
    Venclexta (venetoclax) • Ninlaro (ixazomib) • pomalidomide • bendamustine • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Hemady (dexamethasone tablets)
    2ms
    64007957MMY2022: A Phase II, Open-label, Multicenter Study Testing Teclistamab in Combination withnPomalidomide Administered in Alternative Fashion in Participants with RRMM, whonReceived 1 - 3 Prior Lines of Therapy, Including Lenalidomide and Anti-CD38 Therapy (2025-522114-23-00)
    P1/2, N=35, Not yet recruiting, Odense University Hospital
    New P1/2 trial
    |
    lenalidomide • pomalidomide • Tecvayli (teclistamab-cqyv)
    2ms
    Clinical and immunological effects of adding cyclophosphamide to pomalidomide-dexamethasone in relapsed-refractory multiple myeloma: The randomized MUKseven trial. (PubMed, Br J Haematol)
    Pretreatment CD4+ T-cell levels were identified as a prognostic PFS marker. In summary, our results demonstrate significant effects of cycloaddition to Pd on response and T-cell composition.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    cyclophosphamide • dexamethasone • pomalidomide
    2ms
    DREAMM8: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P3, N=302, Active, not recruiting, GlaxoSmithKline | Trial completion date: Oct 2029 --> Jun 2029
    Trial completion date
    |
    bortezomib • dexamethasone • pomalidomide • Blenrep (belantamab mafodotin-blmf)
    2ms
    DREAMM 8: All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P3, N=21, Active, not recruiting, GlaxoSmithKline | Trial completion date: Nov 2029 --> Jun 2029
    Trial completion date
    |
    bortezomib • dexamethasone • pomalidomide • Blenrep (belantamab mafodotin-blmf)
    2ms
    A fibroblast activation protein degrader enhances cisplatin sensitivity in non‑small cell lung cancer. (PubMed, Oncol Rep)
    In the present study, a fibroblast activation protein (FAP) degrader (Pomalidomide‑PEG2‑FAP2286: FAP‑D) was utilized to enhance cisplatin sensitivity in NSCLC. In conclusion, the study demonstrated that FAP‑D can enhance the cisplatin sensitivity of H1299 cells and NSCLC tumors. The present findings shed new light into promising treatment strategies and demonstrated the potential clinical utility of cisplatin + FAP‑D for NSCLC treatment.
    Journal
    |
    CASP3 (Caspase 3) • DPP4 (Dipeptidyl Peptidase 4)
    |
    cisplatin • pomalidomide • lutetium Lu 177 rofapitide tetraxetan (AAA614)
    2ms
    GEM-BELACOMBOS: Study to Evaluate Efficacy and Safety of Belantamab-based Combinations for Relapsed Multiple Myeloma (clinicaltrials.gov)
    P=N/A, N=100, Not yet recruiting, PETHEMA Foundation
    New trial
    |
    B2M (Beta-2-microglobulin)
    |
    bortezomib • dexamethasone • pomalidomide • Blenrep (belantamab mafodotin-blmf)
    2ms
    Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma (clinicaltrials.gov)
    P1, N=12, Recruiting, University of Michigan Rogel Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    pomalidomide